Introduction
The European Medicines Agency and other national health authorities have recently given marketing authorization for a new ultra-long duration basal insulin analog, insulin degludec (IDeg), and its various preparations in combination with aspart insulin (IDegAsp) and with liraglutide (IDegLira) for the treatment of adults with diabetes mellitus. Currently, the most efficient glucose-lowering treatments for type 1 diabetes (T1DM) and type 2 diabetes (T2DM) in the event of oral antidiabetic drug failure are insulin glargine (IGla) and insulin detemir (IDet). Basal insulin analogs are in fact preferred to neutral protamine Hagedorn insulin because of their longer duration of action 1 and flatter action profile. 2 They are also distinguished by their lower intrapatient variability in hypoglycemic action. 2 Although to date there has been no randomized trial on the efficacy of long-acting basal insulin analogs with regard to reduction of severe hypoglycemia, long-acting basal insulin analog therapy has been demonstrated to confer comparable glycemic control of both overall and nocturnal hypoglycemia. 3 Furthermore, their long-acting effect improves quality of life in patients with T1DM, allowing glycemic control through a single injection compared with the two injections needed when using neutral protamine Hagedorn insulin. Thus, use of these basal insulin analogs should become routine in clinical practice.
IDeg is a novel antiglycemic agent belonging to a therapeutic class of slow insulin analogs. These molecules are characterized by delayed absorption and action. The molecular structure of IDeg is similar to that of the human insulin amino acid sequence except for a modified beta chain, ie, deletion of threonine at position 30 and addition of a 16-carbon fatty diacid to lysine at position 29 ( Figure 1 ). 5 
Ultra-flat action profile and low intrapatient variability
The action of IDeg on the insulin receptor is delayed by two mechanisms. On the one hand, its development is based on the principle of a multi-soluble hexamer. In its pharmaceutical form, before injection, IDeg takes the form of a phenol and zinc formulation containing dihexamers. Once injected, the phenol is quickly eliminated, resulting in formation of multihexamer chains that are released into the subcutaneous tissue. Slow removal of zinc then allows parallel degradation of the multihexamers into monomers, and their gradual entry into the bloodstream. On the other hand, due to the 16-carbon fatty diacid attached at position 29 of the beta chain, the monomers show a high affinity for albumin, further delaying the antiglycemic action. 6 Noteworthy, IDeg differs from IDet in the fatty acid added at position 29, ie, its longer carbon chain (16 in IDeg versus 14 in IDet) as well as its binding to lysine via a glutamic acid spacer in IDeg. This dual mechanism confers IDeg with a slower absorption rate than that of IGla and IDet. The half-life and duration of action of IDeg are 25 hours and 42 hours, IDeg. 7 Studies comparing IDeg with other long-acting insulin analogs have confirmed that IDeg has more stable plasma concentrations. 8 A pharmacological study by Heise et al showed the intrapatient variability to be four times lower using IDeg than IGla in terms of hypoglycemic effect in T1DM patients. Even more interesting in this study was that the intrapatient variability in the IDeg arm remained stable during 24 hours, while in the IGla arm it 
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insulin degludec in type 2 diabetes increased significantly 6-8 hours after injection, reaching its maximum between 14 and 16 hours after injection. 8 In respect to the remarkably flat pharmacokinetic profile of IDeg, several studies have focused on verifying its robustness in the various physiological and pathological contexts commonly encountered in T1DM and T2DM patients. A study of 37 T1DM patients (12 children, 13 adolescents, and 12 adults) confirmed the conservation of this ultra-flat pharmacokinetic profile in children and adolescents. 9 Another study comparing the pharmacokinetic and pharmacodynamic profiles of IDeg in a group of "young T1DM" (18-35 years) and a group of "older DT1" ($65 years) patients after 6 days of subcutaneous injection reported no change in pharmacokinetic and pharmacodynamic properties of IDeg in the older group of patients. 10 Two other studies have investigated the pharmacokinetic profile of IDeg in the presence of chronic renal insufficiency and hepatic impairment and confirmed no changes in these subgroups of patients when compared with healthy volunteers. 11, 12 Given the particularly stable plasma concentrations of IDeg, two main hypotheses should be be evaluated: first, whether IDeg could limit the frequency of hypoglycemic events while allowing glycemic control comparable with that obtained using other long-acting human insulin analogs (IGla and IDet); and second, whether its longer duration of action could provide patients with greater flexibility of administration and thus better quality of life. To test these hypotheses, the BEGIN ® program was conducted in a large T1DM and T2DM population in the form of several Phase III trials to assess the efficacy and safety of IDeg in various indications and in many regimens (Figure 2 found in the extension phase, 14 ie, no significant difference in HbA 1c reduction between the two arms (ETD IGla-IDeg to 0.07% (-0.07, 0.22; P=0.339) and a greater FPG reduction in the IDeg arm versus the IGla arm (ETD IGla-IDeg to -0.36% [-0.67, -0.05], P=0.021). When comparing the BEGIN Once Long studies, the BEGIN Once Long Asia study also compared IDeg versus IGla in insulin-naïve patients, but for a shorter 26-week study period. 15 After 26 weeks of follow-up, both groups showed a comparable reduction in HbA 1c , with an ETD at 0.11% (-0.03, 0.24). However, reduction of fasting plasma glucose was slightly higher in the IGla arm although the ETD was not statistically significant (ETD IDeg -IGla, -0.09 mmol/L [-0.41, 0.23], P=0.59). 15 The BEGIN Basal-Bolus T2 study 16 included T2DM patients who had been treated with insulin for more than 3 months prior to enrollment. The insulin therapy had been delivered as either once-daily basal insulin or in an intensified dosing pattern of basal bolus. There was a similar statistically significant HbA 1c reduction in the IDeg group (-1.10%) and the IGla group (-1.18%) with an ETD of 0.08% (-0.05, 0.21). However, there was a greater (albeit not statistically significant) reduction of fasting plasma glucose (ETD IGla -IDeg, -0.29 [-0.65, 0.06], P=0.1075) in the IDeg group. 16 Finally, the BEGIN Flex T2 study 17 
Degludec insulin and hypoglycemia in T2DM patients
The results of the studies in the BEGIN program are detailed in Table 3 . In respect to the overall hypoglycemia rate, only the BEGIN Basal-Bolus T2 study 16 showed a slightly significant reduction in hypoglycemia in T2DM patients (-18%, P=0.0359). The results of the BEGIN Once Long 13,14 and BEGIN Once Asia 16 studies showed a similar (but not statistically significant) reduction of 18% and 16% at 1 and 2 years IDeg achieved a significant reduction in nocturnal hypoglycemia in insulin-naïve patients (from -36% to -43%) in the BEGIN Once Long study at 1 and 2 years (P=0.038 and P=0.002, respectively) 13, 14 and in T2DM patients treated with basal-bolus in the BEGIN basal-bolus T2 study (-25%, P=0.0399). 16 Finally, on the criterion of severe hypoglycemia, only the BEGIN Once Long study, in insulin-naïve T2DM patients, showed a lower rate of severe hypoglycemia in the IDeg versus IGla arm, ie, 0.14 (P=0.017) versus 0.31 (P=0.023) at 1 and 2 years, respectively. 13, 14 However, the number of events was very low in both groups (seven episodes in 8/257 patients in the IGla group and six episodes in 7/766 patients in the IDeg group) leading to caution in the interpretation of these ratios. Other studies have found comparable data with regard to the severe hypoglycemia rate in IDeg and IGla groups.
More recently, Hollander et al 18 published their latest results for the BEGIN Basal-bolus T2 cohort. After 78 weeks of follow-up, the overall rate of hypoglycemia was 24% lower (P=0.011) and the rate of nocturnal hypoglycemia was 31% lower (P=0.016) in the IDeg group, with similar glycemic control in both groups.
A recent meta-analysis 19 of five studies in T2DM showed higher efficacy of IDeg versus IGla in reduction of overall . Finally, the same meta-analysis reported a statistically significant reduction in overall (-25%) and nocturnal (-38%) hypoglycemia rates during the maintenance period. These data suggest a long-term beneficial effect of IDeg after its optimal dose is achieved.
Towards a therapeutic regimen with IDeg three times a week?
The ultra-long duration of action of IDeg allows longer injection intervals while maintaining consistent glycemic control, so it might be beneficial in specific patient populations, especially insulin-naïve T2DM patients. BEGIN Easy AM/BEGIN Easy PM 20 studied such an hypothesis by comparing administration of IDeg three times a week (3TW) in the morning (AM) and evening (PM), respectively, with administration of IGla once daily. BEGIN Easy AM included 460 patients in two arms, ie, IDeg 3TWAM (n=230) and IGla once daily (n=230). The BEGIN Easy PM study included 467 patients in two arms, ie, IDeg 3TWPM , (n=233) and IGla once daily (n=234). The duration of the studies was 26 weeks in both cases. Unfortunately, on the criterion of HbA 1c , noninferiority of IDeg 3TW was not shown in either of the two trials, with an ETD of 0.34% (0. 18 
Insulin degludec: which titration algorithm is the most effective?
The ultra-long duration of action of IDeg, ie, more than 24 hours, might not be relevant in dose adjustment from fasting prebreakfast glycemia, which is commonly used for titration of other long-acting analogs. The BEGIN Once Single Use 21 study aimed to identify the best titration modality for adjusting the IDeg dose, using a "simple" algorithm allowing dose adjustment according to a prebreakfast selfmeasured plasma glucose versus a "step-wise" algorithm allowing dose adjustment according to the lowest prebreakfast self-measured plasma glucose in the last 3 days. Patients (n=222) were randomly assigned into two arms, ie, IDeg simple and IDeg
Step-Wise . The HbA 1c decreased similarly in both arms (-1.09% in IDeg simple versus -0.93% in IDeg Step-Wise ) with an ETD of -0.16% (-0.39, 0.07). The overall and nocturnal hypoglycemia rates were not significantly different. The authors concluded that both algorithms showed comparable effectiveness and tolerance, suggesting the possibility of using the two algorithms according to patient preference.
Other forms of insulin degludec for T2DM patients
Other forms of IDeg have been developed for use in T2DM patients, including IDeg-IAsp and IDeg-liraglutide (IDeg-Lira) preparations; the former is a soluble coformulation of IDeg and IAsp (70% IDeg and 30% IAsp). In a study by Onishi et al, 22 IDegAsp was compared with IGla alone. After 26 weeks, mean HbA 1c was lower in the IDegAsp arm (7.0%) than in the IGla arm (7.3%), with an ETD (IDegAsp -IGla) of -0.28% (-0.46, -0.10, P,0.01). Further, IDegAsp was associated with lower rates of overall and nocturnal hypoglycemia versus IGla, but the ERRs of 0.73 (0.50, 1.08) and 0.75 (0.34, 1.64) were not statistically significant.
In the BOOST trials, 23, 24 IDegAsp was compared with premixed biphasic insulin aspart 30 24 with a lower total daily insulin dose in IDegAsp versus biphasic insulin aspart 30. In the former trial, rates of overall and severe hypoglycemia were similar in both groups, while the rate of confirmed nocturnal hypoglycemia was lower with IDegAsp (ERR 0.67 [0.43, 1.06]), but not statistically significant. In the trial by Fulcher et al, rates of overall and confirmed nocturnal hypoglycemia were lower in the IDegAsp group (ERR 0.68 [0.52, 0.89] P=0.0049 and 0.27 [0.18, 0.41], P,0.0001, respectively). In the maintenance period, rates of severe hypoglycemia were also lower for IDegAsp (P=0.04), with one episode in the IDegAsp group versus 13 episodes in the biphasic insulin aspart 30 group. These two studies suggest an equivalent efficacy of IDegAsp versus biphasic insulin aspart 30 for HbA 1c reduction, with a decreased risk of overall and nocturnal hypoglycemia and probably a reduction of severe hypoglycemia in the maintenance period.
The ADA and EASD recently approved the combination of basal insulin and a GLP-1 receptor agonist. 4 IDegLira, a novel combination of basal IDeg and the long-acting GLP-1 analog liraglutide, was then developed for the treatment of T2DM patients as a once-daily, single subcutaneous injection. The pharmacological rationale for use of this combination is that lower fasting blood glucose levels can be obtained using IDeg and liraglutide, while liraglutide can also modestly reduce post-prandial glucose excursions. 25 The DUAL-I showed noninferiority of IDegLira versus IDeg alone, with an ETD of -0.47% (-0.58, -0.36, P,0.0001). The same trial showed the superiority of IDegLira versus liraglutide (ETD -0.64% (-0.75, -0.53, P,0.0001). 26 The DUAL-2 trial showed the superiority of IDegLira versus IDeg alone in terms of HbA 1c reduction (-1.9% in the IDegLira arm versus -0.9% in the IDeg arm; ETD -1.1% [-1.3, -0.8], P,0.0001) and mean weight reduction. 27 However, the hypoglycemia rate was comparable in both groups.
Finally, the BEGIN Victoza Add-On study 28 compared IDeg + IAsp versus IDeg + liraglutide in a T2DM population from the BEGIN Once Long extension cohort.
14 Patients were randomized to IDeg + liraglutide and IDegAsp if the target HbA 1c ($7.0%) was not reached at 104 weeks. If their HbA 1c was ,7.0%, patients continued IDeg in a third nonrandomized arm. The results showed than IDeg + liraglutide (-0.74%) reduced HbA 1c significantly more than IDeg + IAsp (-0.39%), with an ETD of -0.32% (-0.53, -0.12, P=0.0024). Further, patients on IDeg + liraglutide had significantly less overall and nocturnal hypoglycemia, and significantly greater weight loss (-2. 29 The BEGIN Compare study compared IDeg 200 IU/mL with IDeg 100 IU/mL, and the results showed comparable efficacy between the groups with regard to glycemic control and hypoglycemia rates.
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Insulin degludec and quality of life in T2DM patients
In addition to assessment of efficacy and safety criteria, there are at least two hypotheses concerning assessment of quality of life related to the use of an antiglycemic agent. T2DM patients treated with IDeg may feel less stress than those treated with antiglycemic agents administered on a strict schedule. Moreover, the significant reduction in nocturnal hypoglycemia rate achieved by IDeg could be a factor in improving quality of life in T2DM patients. It is known that hypoglycemia-related anxiety is associated with deterioration of quality of life in patients with diabetes. 31 A recent meta-analysis 32 addressed this issue using the Short-Form 36 questionnaire filled in by patients (T2DM patients in five trials and T1DM patients in one trial. These results were then processed and converted into a EuroQol-5D score. The metaanalysis concluded that there was a moderate but significant improvement in quality of life in patients treated with IDeg when compared with those treated with IGla. This improvement was independent of the flexibility of administration, ie, IDeg was injected at a fixed time once daily. Further studies are needed to better understand the benefits of IDeg on quality of life in T2DM patients.
Insulin degludec safety and adverse effects General adverse effects
Several studies have evaluated the safety of IDeg. To date, no study has shown either more or serious adverse events in patients treated with IDeg compared with those treated with IGla. Moreover, according to this review, the proportion of patient drop outs was not different among studies. In terms of the IDeg doses used, tests in T2DM patients showed no obvious difference between insulin doses in the IDeg and IGla groups. According to the literature, comparable weight gain results were obtained in T2DM patients treated with IDeg compared with those treated with IGla. It is worth mentioning that immunological studies have found insignificant traces of anti-degludec antibody in T2DM patients. 13, 17 As a result, the currently available data on use of IDeg in daily clinical practice seem reassuring. However, the limitations of trial duration and sample size in the current literature on the safety of IDeg preclude any results being able to be considered conclusive. Larger and longer duration randomized prospective trials on IDeg-related adverse events and serious adverse events are needed to obtain evidence-based and conclusive data. Two important criteria regarding the safety of IDeg need to be further evaluated, ie, cardiovascular safety and risk of neoplasia.
Cardiovascular safety
This systemic review highlights the limitations of the available published trials, ie, short observation periods and small sample sizes. Consequently, there are no current conclusive data on the cardiovascular safety of IDeg. However, a 2012 US Food and Drug Administration study of randomized Phase III trials in T1DM and T2DM patients reported a potential cardiovascular risk associated with IDeg. Indeed, in most of the trials comparing IDeg/IDegAsp with a comparator arm, the incidence of cardiovascular events was estimated according to composite criteria of MACE (major adverse cardiovascular events) and MACE+. The latter criterion estimated the occurrence of events during follow-up, ie, acute coronary syndrome, including unstable angina and myocardial infarction, stroke, and cardiovascular death. The definition of cardiovascular events according to the MACE criterion was stricter than that by MACE+ and excluded unstable angina. All events occurring 7 days after cessation of treatment were censored. According to the MACE+ criterion, 95/5,794 events in the IDeg/IDegAsp group versus 37/3,461 in the comparator group were observed (hazard ratio 1.30; 95% confidence interval 0.88-1.93). According to the MACE criterion, there were 70/5,794 events in the IDeg/IDegAsp group versus 21/3,461 in the comparator group (hazard ratio 1.67; 95% confidence interval 1.01-2.75). The number of cardiovascular events according to the MACE criterion was then more statistically significant in IDeg/IDegAsp group.
Given the above data, although limited and not representing those in the general diabetes patient population, the US Food and Drug Administration has delayed the marketing authorization for IDeg, and requested additional prospective randomized studies on the cardiovascular safety of IDeg. In contrast, the European Medicines Agency and other national health authorities have granted marketing authorization for IDeg. Such divergence in marketing authorization approvals has generated debate on the potential cardiovascular risk of IDeg. To date, there is no relevant evidence-based rationale to explain any potential IDeg-associated cardiovascular risk. The DEVOTE (NCT 01959529) trial is in progress, and is aiming to enroll 7,500 T2DM subjects at high cardiovascular risk (age $50 years with a history of cardiovascular disease or diabetic nephropathy or age $60 years with cardiovascular risk factors) in order to evaluate such an hypothesis. The results of this trial are expected to be available in 2018. However, according to Novo Nordisk, it seems that the US Food and Drug Administration has accepted a resubmitted marketing authorization application based on interim analysis of data from the DEVOTE study.
Risk of neoplasia
In 2009, some cohort studies 33, 34 raised the issue of a potentially increased risk of cancer in T2DM patients treated with IGla. To date, no study has demonstrated the increased risk of cancer in T2DM patients on IGla therapy. 35 The suspicion of a potential risk of neoplasia in T2DM patients treated with IGla has been explained based on the theoretical capacity of IGla to have insulin-like growth factor 1 (IGF-1)-like activity after its interaction with the IGF-1 receptor. Indeed, several studies have shown a greater affinity of IGla compared with that of human insulin for the IGF-1 receptor in vitro. 36 This greater affinity can be explained by the addition of arginine residues at positions 31 and 32 of the beta chain, thus suggesting an increased risk of cancer in patients treated with IGla. In contrast, in vivo metabolism of IGla in blood shows low mitogenic activity due to the low affinity of its primary metabolite for the IGF-1 receptor. 37 In respect to IDeg, data from the study by Nishimura et al showed a lower affinity of IDeg for the IGF-1 receptor in comparison with that of human insulin. 38 These results theoretically suggest the absence of increased risk in patients treated with IDeg. However, clinically, the duration of this study does not allow an evidencebased conclusion to be reached. The results of the BEGIN Once Long trial in insulin-naïve T2DM patients followed for 1 year showed a very low rate of cancer in the IDeg and IGla groups (1.0% [8/766] in the IDeg group and 0.8% [2/257] in the IGla group). 13 A prospective cohort with long-term follow-up is therefore needed to better assess this risk.
Conclusion
In conclusion, the study results suggest that IDeg provides glycemic control and reduction of nocturnal hypoglycemia comparable with that achieved by other long-acting analogs (IGla and IDet) in patients with T2DM. The rate of severe hypoglycemia also seems to be reduced when using IDeg therapy; however, long-term follow-up is warranted for monitoring of possible but relatively infrequent adverse events. On the other hand, a 2012 US Food and Drug Administration study revealed a potential IDeg-associated cardiovascular risk. Future prospective evaluation of large cohorts of T2DM patients treated with IDeg, with long-term follow-up, can provide more relevant information on the safety of IDeg therapy.
